<div id="readability-page-1"><p>Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 995 shares of the company's stock in a transaction on Monday, December 15th. The stock was sold at an average price of $11.90, for a total value of $11,840.50. Following the sale, the insider owned 136,878 shares of the company's stock, valued at approximately $1,628,848.20. This represents a 0.72% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink.</p><div><p><span></span><span>Get <strong>Cullinan Therapeutics</strong> alerts:</span></p></div><p>Jennifer Michaelson also recently made the following trade(s): </p><ul><li>On Friday, December 12th, Jennifer Michaelson sold 2,148 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $12.38, for a total value of $26,592.24. </li><li>On Monday, November 24th, Jennifer Michaelson sold 4,000 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.30, for a total value of $49,200.00. </li></ul><h2>Cullinan Therapeutics Stock Performance</h2><p>CGEM traded down $0.60 on Tuesday, hitting $10.22. The company had a trading volume of 1,140,331 shares, compared to its average volume of 646,330. The stock has a market capitalization of $603.76 million, a price-to-earnings ratio of -3.09 and a beta of -0.11. The stock has a fifty day moving average price of $9.09 and a 200-day moving average price of $8.08. Cullinan Therapeutics, Inc. has a 12-month low of $5.68 and a 12-month high of $13.33. </p><p>Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.77) earnings per share for the quarter, beating analysts' consensus estimates of ($0.95) by $0.18.  Analysts forecast that  Cullinan Therapeutics, Inc. will post -3.04 EPS for the current fiscal year. </p><h2>Analysts Set New Price Targets</h2><p>CGEM has been the topic of several analyst reports. Wedbush lifted their price target on shares of Cullinan Therapeutics from $25.00 to $34.00 and gave the stock an &#34;outperform&#34; rating in a report on Tuesday, December 9th. Wall Street Zen raised Cullinan Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 22nd. BTIG Research upped their target price on Cullinan Therapeutics from $32.00 to $38.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, November 24th. HC Wainwright increased their price target on Cullinan Therapeutics from $24.00 to $26.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, November 20th. Finally, Morgan Stanley dropped their price target on Cullinan Therapeutics from $35.00 to $28.00 and set an &#34;overweight&#34; rating on the stock in a research note on Monday, August 18th. Six equities research analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has assigned  a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $28.29.</p><p><b>Check Out Our Latest Stock Analysis on CGEM</b></p><h2>Hedge Funds Weigh In On Cullinan Therapeutics</h2><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL lifted its position in  Cullinan Therapeutics by 30.9% during the 3rd quarter. Tudor Investment Corp ET AL now owns 28,988 shares of the company's stock worth $172,000 after acquiring an additional 6,850 shares during the period.  XTX Topco Ltd raised its stake in shares of  Cullinan Therapeutics by 289.8% in the third quarter. XTX Topco Ltd now owns 167,979 shares of the company's stock worth $996,000 after purchasing an additional 124,884 shares during the last quarter.  Qube Research &amp; Technologies Ltd lifted its holdings in shares of  Cullinan Therapeutics by 127.1% during the third quarter. Qube Research &amp; Technologies Ltd now owns 152,409 shares of the company's stock worth $904,000 after purchasing an additional 85,290 shares during the period.  Prelude Capital Management LLC lifted its holdings in shares of  Cullinan Therapeutics by 201.2% during the third quarter. Prelude Capital Management LLC now owns 48,652 shares of the company's stock worth $289,000 after purchasing an additional 32,500 shares during the period.  Finally, Millennium Management LLC boosted its position in  Cullinan Therapeutics by 7.8% in the third quarter. Millennium Management LLC now owns 550,471 shares of the company's stock valued at $3,264,000 after buying an additional 39,643 shares during the last quarter. Hedge funds and other institutional investors own  86.31% of the company's stock. </p><h2>About Cullinan Therapeutics</h2> (Get Free Report)<p>Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.</p><h2>See Also</h2><ul><li>Five stocks we like better than Cullinan Therapeutics</li><li>The Basics of Support and  Resistance</li><li>RTX Surges to Record Highs as Defense Orders Explode</li><li>How to Short a Stock in 5 Easy Steps </li><li>Smart Money Is Buying Auto Suppliers, Not Car Brands</li><li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li><li>Higher Beef Prices Are Here: Best Steakhouse Stocks for 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dFTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dFTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cullinan Therapeutics Right Now?</h2><p>Before you consider Cullinan Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list.</p><p>While Cullinan Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CGEM

<p>Cullinan Therapeutics insider Jennifer Michaelson sold 995 shares at $11.90 each, totaling $11,840.50. Post-sale, she owns 136,878 shares, a 0.72% decrease in her position. The transaction was disclosed in an SEC filing. Recent trades include selling 2,148 shares at $12.38 and 4,000 shares at $12.30. The stock's recent performance shows a decrease to $10.22, with a market cap of $603.76 million. Analysts have set new price targets, with a consensus rating of 'Moderate Buy' and an average target of $28.29.</p>

Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 995 Shares